calciol Compound · CHEBI:28940 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 24 findings 9 endpoints 20 papers Studied for Serum 25-hydroxyvitamin D concentration , Expanded Disability Status Scale (EDSS) and All-cause mortality , and 6 more
Evidence from moderate to insufficient across 24 findings
(-)-epigallocatechin 3-gallate Compound · CHEBI:4806 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 20 findings 16 endpoints 14 papers Studied for Maximal oxygen uptake , Glycated haemoglobin (HbA1c) and HOMA-IR , and 13 more
Evidence from limited to insufficient across 20 findings
lutein Compound · CHEBI:28838 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 19 findings 15 endpoints 11 papers Studied for Working memory performance , Macular pigment optical density and Serum or plasma lutein concentration , and 12 more
Evidence from moderate to insufficient across 19 findings
empagliflozin Compound · CHEBI:82720 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 19 findings 13 endpoints 7 papers Studied for Interleukin-6 concentration , Alanine aminotransferase and Fasting blood glucose , and 10 more
Evidence from moderate to very limited across 19 findings
Zn(2+) Element · CHEBI:29105 Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. 17 findings 16 endpoints 7 papers Studied for Diarrhoea duration , Triglycerides and Adverse event occurrence (oral or enteral supplement) , and 13 more
Evidence from strong to very limited across 17 findings
pravastatin Compound · CHEBI:63618 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 16 findings 11 endpoints 5 papers Studied for Birth weight , C-reactive protein concentration and LDL cholesterol , and 8 more
Evidence from moderate to very limited across 16 findings
Ca(2+) Element · CHEBI:29108 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 16 findings 11 endpoints 11 papers Studied for Pre-eclampsia incidence , Gestational hypertension incidence and Preterm birth incidence , and 8 more
Evidence from moderate to very limited across 16 findings
L-ascorbic acid Compound · CHEBI:29073 Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. 15 findings 14 endpoints 12 papers Studied for Intensive care unit length of stay , Posterior subcapsular cataract incidence and Cortical cataract incidence , and 11 more
Evidence from strong to insufficient across 15 findings
crocin-1 Compound · CHEBI:79068 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 14 findings 12 endpoints 5 papers Studied for Triglycerides , Beck Depression Inventory (BDI) total score and Pittsburgh Sleep Quality Index global score , and 9 more
Evidence from moderate to very limited across 14 findings
α-tocopherol Compound · CHEBI:22470 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 14 findings 14 endpoints 7 papers Studied for Oesophageal cancer incidence , Alanine aminotransferase and Ovarian cancer incidence , and 11 more
Evidence from moderate to very limited across 14 findings
methylene blue Compound · CHEBI:6872 Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. 13 findings 9 endpoints 9 papers Studied for Hospital length of stay , All-cause mortality and Intensive care unit length of stay , and 6 more
Evidence from strong to insufficient across 13 findings
sodium benzoate Compound · CHEBI:113455 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 13 findings 12 endpoints 8 papers Studied for Reduced glutathione concentration
Evidence from very limited to insufficient across 13 findings
all-cis-5,8,11,14,17-icosapentaenoic acid Compound · CHEBI:28364 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 12 findings 9 endpoints 8 papers Studied for Erythrocyte sedimentation rate , LDL cholesterol and Serum albumin , and 6 more
Evidence from moderate to insufficient across 12 findings
tirzepatide Compound · CHEBI:194186 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 12 findings 8 endpoints 4 papers Studied for Systolic blood pressure (setting unspecified) , Glycated haemoglobin (HbA1c) and Fasting blood glucose , and 5 more
selenium atom Compound · CHEBI:27568 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 11 findings 10 endpoints 4 papers Studied for Serum free triiodothyronine (FT3) , Total antioxidant capacity and C-reactive protein concentration , and 7 more
Evidence from moderate to limited across 11 findings
lycopene Compound · CHEBI:15948 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 11 findings 9 endpoints 9 papers Studied for Incidence of stroke , Flow-mediated dilation and Interleukin-6 concentration , and 6 more
Evidence from moderate to insufficient across 11 findings
(R)-carnitine Compound · CHEBI:16347 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 11 findings 8 endpoints 6 papers Studied for C-reactive protein concentration , Systolic blood pressure (setting unspecified) and Fasting blood glucose , and 5 more
Evidence from moderate to limited across 11 findings
lipoic acid Compound · CHEBI:16494 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 11 findings 10 endpoints 5 papers Studied for Triglycerides , HOMA-IR and Body mass , and 7 more
Evidence from moderate to very limited across 11 findings
glucosamine Compound · CHEBI:5417 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 10 findings 8 endpoints 8 papers Studied for WOMAC pain subscale , All-cause mortality and Lung cancer incidence , and 5 more
Evidence from moderate to very limited across 10 findings
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Compound · CHEBI:28125 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 10 findings 10 endpoints 9 papers Studied for Adverse event occurrence (oral or enteral supplement) , Necrotising enterocolitis incidence and Birth weight , and 7 more
Evidence from moderate to insufficient across 10 findings
L-citrulline Compound · CHEBI:16349 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 10 findings 7 endpoints 8 papers Studied for Flow-mediated dilation , Sequential Organ Failure Assessment (SOFA) total score and HOMA-IR , and 4 more
Evidence from moderate to insufficient across 10 findings
chromium(3+) Compound · CHEBI:49544 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 10 findings 8 endpoints 3 papers Studied for Fasting blood glucose , HDL cholesterol and HOMA-IR , and 5 more
Evidence from moderate to very limited across 10 findings
aspartame Compound · CHEBI:2877 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 9 findings 8 endpoints 5 papers Studied for Body mass
Evidence from very limited to insufficient across 9 findings
NMN zwitterion Compound · CHEBI:16171 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 9 findings 9 endpoints 3 papers Studied for HOMA-IR , Diastolic blood pressure (setting unspecified) and Alanine aminotransferase , and 6 more
Evidence from moderate to very limited across 9 findings
taurine Compound · CHEBI:507393 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 8 findings 6 endpoints 3 papers Studied for Diastolic blood pressure (setting unspecified) , Systolic blood pressure (setting unspecified) and Serum creatine kinase activity , and 3 more
spironolactone Compound · CHEBI:9241 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 8 findings 8 endpoints 4 papers Studied for Mitral E/e' ratio , 24-hour ambulatory systolic blood pressure and All-cause mortality , and 5 more
Evidence from moderate to very limited across 8 findings
N-acetyl-L-cysteine Compound · CHEBI:28939 Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. 7 findings 5 endpoints 5 papers Studied for All-cause mortality , Serum creatine kinase activity and Acute kidney injury incidence (any grade) , and 2 more
Evidence from strong to limited across 7 findings
quercetin Compound · CHEBI:57694 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 7 findings 7 endpoints 4 papers Studied for Visual analogue scale pain intensity , Postoperative atrial fibrillation incidence and Diastolic blood pressure (setting unspecified) , and 4 more
Evidence from moderate to very limited across 7 findings
ursolic acid Compound · CHEBI:9908 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 7 findings 4 endpoints 3 papers chondroitin sulfate Compound · CHEBI:37397 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 6 findings 5 endpoints 6 papers Studied for Serious adverse event incidence , Radiographic joint-space narrowing and WOMAC stiffness subscale , and 2 more
Evidence from very limited to insufficient across 6 findings
vitamin D2 Compound · CHEBI:28934 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 6 findings 5 endpoints 3 papers Studied for C-reactive protein concentration , HDL cholesterol and Total cholesterol (TC) , and 2 more
Evidence from moderate to very limited across 6 findings
sodium hydrogencarbonate Compound · CHEBI:32139 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 6 findings 4 endpoints 4 papers Studied for All-cause mortality , Duration of mechanical ventilation and Intensive care unit length of stay , and 1 more
Evidence from moderate to limited across 6 findings
fucoxanthin Compound · CHEBI:5186 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 6 findings 5 endpoints 6 papers Studied for TLR4 , EPHB2 and KEAP1 , and 2 more
Evidence from very limited to insufficient across 6 findings
L-cysteine Compound · CHEBI:17561 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 6 findings 6 endpoints 2 papers Studied for Reduced glutathione concentration , Necrotising enterocolitis incidence and Intraventricular haemorrhage incidence , and 3 more
Evidence from moderate to very limited across 6 findings
5-hydroxy-L-tryptophan Compound · CHEBI:17780 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 6 findings 5 endpoints 6 papers Studied for Fat mass , Body mass and Cortisol concentration , and 2 more
Evidence from very limited to insufficient across 6 findings
nicotinamide Compound · CHEBI:17154 Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. 6 findings 6 endpoints 3 papers Studied for Melanoma incidence , HDL cholesterol and Triglycerides , and 3 more
Evidence from strong to very limited across 6 findings
L-isoleucine Compound · CHEBI:17191 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 6 findings 6 endpoints 5 papers Studied for Postprandial blood glucose area under the curve and Peak postprandial blood glucose , and 4 more
Evidence from very limited to insufficient across 6 findings
sodium(1+) Element · CHEBI:29101 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 5 findings 5 endpoints 4 papers Studied for Peak postprandial blood glucose and Expanded Disability Status Scale (EDSS) , and 3 more
Evidence from moderate to very limited across 5 findings
methylphenidate Compound · CHEBI:6887 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 5 findings 4 endpoints 4 papers Studied for Working memory performance , Serious adverse event incidence and Hamilton Depression Rating Scale (HDRS) total score , and 1 more
Evidence from limited to very limited across 5 findings
Collagen Compound · CHEBI:3815 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 5 findings 5 endpoints 5 papers Studied for Stratum corneum hydration (corneometry) , Physical function (pooled across scales) and Visual analogue scale pain intensity , and 2 more
Evidence from moderate to very limited across 5 findings
sucralose Compound · CHEBI:32159 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 5 findings 5 endpoints 4 papers Studied for Peak postprandial blood glucose , HOMA-IR and Fasting blood glucose , and 2 more
Evidence from limited to very limited across 5 findings
thiamine Compound · CHEBI:18385 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 5 findings 3 endpoints 4 papers Studied for Fasting blood glucose , Glycated haemoglobin (HbA1c) and All-cause mortality
Evidence from moderate to limited across 5 findings
L-leucine Compound · CHEBI:15603 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 5 findings 4 endpoints 5 papers Studied for Plasma glucagon-like peptide-1 (GLP-1)
Evidence from moderate to insufficient across 5 findings
folic acid Compound · CHEBI:27470 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 4 papers Studied for Colorectal cancer incidence , Interleukin-6 concentration and Fasting blood glucose , and 1 more
sodium nitrite Compound · CHEBI:78870 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 3 endpoints 4 papers Studied for Systemic vascular resistance and Plasma nitrite concentration , and 1 more
Evidence from moderate to insufficient across 4 findings
riboflavin Compound · CHEBI:17015 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 4 papers Studied for Adverse event occurrence (oral or enteral supplement) and Erythrocyte glutathione reductase activation coefficient (EGRac) , and 2 more
Evidence from moderate to insufficient across 4 findings
myo-inositol Compound · CHEBI:17268 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 3 endpoints 4 papers Studied for HOMA-IR and Gestational diabetes mellitus incidence , and 1 more
Evidence from moderate to very limited across 4 findings
finasteride Compound · CHEBI:5062 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 2 papers Studied for Prostate cancer incidence , Serum prostate-specific antigen and Total testosterone , and 1 more
naringenin Compound · CHEBI:50202 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 4 findings 4 endpoints 1 paper L-cystine Compound · CHEBI:16283 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 4 findings 4 endpoints 3 papers Studied for SLC7A11
Evidence from very limited to insufficient across 4 findings
paroxetine Compound · CHEBI:7936 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 3 papers Studied for Withdrawal due to adverse events , Hamilton Depression Rating Scale (HDRS) total score and Antidepressant treatment response rate , and 1 more
choline Compound · CHEBI:15354 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 3 papers Studied for Incidence of cardiovascular disease (composite) , Mini-Mental State Examination total score and HOMA-IR , and 1 more
Evidence from moderate to limited across 4 findings
triclosan Compound · CHEBI:164200 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 2 endpoints 4 papers Studied for Wound infection incidence and Birth weight
Evidence from moderate to very limited across 4 findings
rebaudioside A Compound · CHEBI:145012 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 4 findings 4 endpoints 2 papers quetiapine Compound · CHEBI:8707 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 3 endpoints 2 papers Studied for Withdrawal due to adverse events , Antidepressant treatment response rate and Serious adverse event incidence
piperine Compound · CHEBI:28821 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 1 paper Studied for Alanine aminotransferase , Aspartate aminotransferase and Triglycerides , and 1 more
bisphenol A Compound · CHEBI:33216 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 4 endpoints 4 papers Studied for Gestational age at delivery (length of gestation) , Breast cancer incidence and HOMA-IR , and 1 more
Evidence from moderate to very limited across 4 findings
cannabidiol Compound · CHEBI:69478 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 4 findings 3 endpoints 4 papers Studied for Serious adverse event incidence , Withdrawal due to adverse events and Seizure frequency 50% responder rate
pectin Compound · CHEBI:17309 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 3 findings 3 endpoints 1 paper acrylamide Compound · CHEBI:28619 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 3 findings 3 endpoints 3 papers Studied for Pancreatic cancer incidence and Type 2 diabetes incidence , and 1 more
Evidence from moderate to very limited across 3 findings
titanium dioxide Compound · CHEBI:32234 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 3 findings 3 endpoints 1 paper Studied for C-reactive protein concentration , Total antioxidant capacity and Tumour necrosis factor alpha concentration
atorvastatin Compound · CHEBI:39548 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 3 findings 2 endpoints 2 papers Studied for Serum adiponectin
Evidence from moderate to very limited across 3 findings
fluconazole Compound · CHEBI:46081 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 3 findings 3 endpoints 1 paper Studied for All-cause mortality , Hospital length of stay and Withdrawal due to adverse events
beta-alanine Compound · CHEBI:57966 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 3 findings 3 endpoints 2 papers Studied for Rating of perceived exertion and Time to exhaustion , and 1 more
Evidence from moderate to very limited across 3 findings
sertraline Compound · CHEBI:9123 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 3 findings 3 endpoints 2 papers Studied for Interleukin-6 concentration and Tumour necrosis factor alpha concentration , and 1 more
Evidence from moderate to very limited across 3 findings
iodide Compound · CHEBI:16382 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Serum thyroid-stimulating hormone (TSH)
Evidence from moderate to very limited across 2 findings
3,4-methylenedioxymethamphetamine Compound · CHEBI:1391 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 1 paper Studied for Systolic blood pressure (setting unspecified) and Diastolic blood pressure (setting unspecified)
iron(2+) Element · CHEBI:29033 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 1 endpoint 2 papers Studied for All-cause mortality
Evidence from moderate to very limited across 2 findings
escitalopram Compound · CHEBI:36791 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Antidepressant treatment response rate and Beck Depression Inventory (BDI) total score
zolpidem Compound · CHEBI:10125 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Total sleep time and Visual analogue scale pain intensity
phosphate(3-) Compound · CHEBI:18367 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 2 findings 1 endpoint 2 papers phylloquinone Compound · CHEBI:18067 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 1 paper Studied for Femoral neck bone mineral density and Lumbar spine bone mineral density
sulforaphane Compound · CHEBI:47807 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Working memory performance and Triglycerides
glycine betaine Compound · CHEBI:17750 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Countermovement jump height
Evidence from moderate to very limited across 2 findings
linoleic acid Compound · CHEBI:17351 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Incidence of coronary heart disease
Evidence from moderate to very limited across 2 findings
testosterone Compound · CHEBI:17347 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 2 findings 2 endpoints 2 papers Studied for Clinical pregnancy rate
all-trans-retinol Compound · CHEBI:17336 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Duration of mechanical ventilation
Evidence from moderate to very limited across 2 findings
L-tyrosine Compound · CHEBI:58315 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 2 findings 2 endpoints 2 papers Studied for Time to exhaustion and Peak power output
meloxicam Compound · CHEBI:6741 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 1 paper Studied for Time to first postoperative analgesic request and Hospital length of stay
apixaban Compound · CHEBI:72296 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 1 paper Studied for All-cause mortality and Incidence of stroke
natamycin Compound · CHEBI:7488 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 2 findings 2 endpoints 2 papers acetylsalicylic acid Compound · CHEBI:15365 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 2 findings 2 endpoints 1 paper Studied for Total leukocyte count and CD4/CD8 ratio
propranolol Compound · CHEBI:8499 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Withdrawal due to adverse events and All-cause mortality
dapagliflozin Compound · CHEBI:85078 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 2 findings 2 endpoints 2 papers K(+) Element · CHEBI:29103 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 2 findings 2 endpoints 2 papers Studied for Flow-mediated dilation and All-cause mortality
Evidence from moderate to limited across 2 findings
azithromycin Compound · CHEBI:2955 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 2 findings 2 endpoints 2 papers Studied for Duration of mechanical ventilation
ethanol Compound · CHEBI:16236 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper montelukast Compound · CHEBI:50730 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Forced expiratory volume in one second (FEV1)
pantoprazole Compound · CHEBI:7915 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Intensive care unit length of stay
indigo carmine Compound · CHEBI:31695 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper warfarin Compound · CHEBI:10033 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
glycine Compound · CHEBI:57305 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
biotin Compound · CHEBI:57586 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Expanded Disability Status Scale (EDSS)
morphine Compound · CHEBI:17303 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
trazodone Compound · CHEBI:9654 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Pittsburgh Sleep Quality Index global score
steviol glycoside Compound · CHEBI:145027 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 1 finding 1 endpoint 1 paper erythritol Compound · CHEBI:17113 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Ad libitum test-meal energy intake
malic acid Compound · CHEBI:6650 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper prednisone Compound · CHEBI:8382 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Visual analogue scale pain intensity
metformin Compound · CHEBI:6801 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
calcium carbonate Compound · CHEBI:3311 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper maltitol Compound · CHEBI:68428 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper permethrin Compound · CHEBI:34911 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
fluoride Compound · CHEBI:17051 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 1 finding 1 endpoint 1 paper Studied for Gestational diabetes mellitus incidence
duloxetine Compound · CHEBI:36796 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Visual analogue scale pain intensity
methylcob(III)alamin Compound · CHEBI:28115 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 1 finding 1 endpoint 1 paper zeaxanthin Compound · CHEBI:27547 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper rosuvastatin Compound · CHEBI:38545 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Diastolic blood pressure (setting unspecified)
pyridoxine Compound · CHEBI:16709 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 1 finding 1 endpoint 1 paper sodium chloride Compound · CHEBI:26710 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 1 finding 1 endpoint 1 paper Studied for Plasma glucagon-like peptide-1 (GLP-1)
L-valine Compound · CHEBI:16414 The <small>L</small>-enantiomer of valine. Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper gabapentin Compound · CHEBI:42797 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Anxiety symptom severity (pooled across unnamed instruments)
sodium ascorbate Compound · CHEBI:113451 Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. 1 finding 1 endpoint 1 paper Cu(2+) Compound · CHEBI:29036 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Gestational age at delivery (length of gestation)
furosemide Compound · CHEBI:47426 Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. 1 finding 1 endpoint 1 paper Studied for All-cause mortality
aripiprazole Compound · CHEBI:31236 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 1 finding 1 endpoint 1 paper sucrose Compound · CHEBI:17992 Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. 1 finding 1 endpoint 1 paper Mn(2+) Compound · CHEBI:29035 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Birth weight
cyanocob(III)alamin Compound · CHEBI:17439 Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. 1 finding 1 endpoint 1 paper Studied for Prostate cancer incidence